MX2017010323A - Formulaciones farmaceuticas de inhibidor de esterasa c1. - Google Patents
Formulaciones farmaceuticas de inhibidor de esterasa c1.Info
- Publication number
- MX2017010323A MX2017010323A MX2017010323A MX2017010323A MX2017010323A MX 2017010323 A MX2017010323 A MX 2017010323A MX 2017010323 A MX2017010323 A MX 2017010323A MX 2017010323 A MX2017010323 A MX 2017010323A MX 2017010323 A MX2017010323 A MX 2017010323A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulations
- esterase inhibitor
- inh
- ameliorated
- exhibiting
- Prior art date
Links
- 229940009550 c1 esterase inhibitor Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000055157 Complement C1 Inhibitor Human genes 0.000 abstract 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 abstract 1
- 102000002397 Kinins Human genes 0.000 abstract 1
- 108010093008 Kinins Proteins 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15156010 | 2015-02-20 | ||
| PCT/EP2016/053559 WO2016131958A1 (en) | 2015-02-20 | 2016-02-19 | Pharmaceutical formulations of c1 esterase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017010323A true MX2017010323A (es) | 2017-12-07 |
Family
ID=52573617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010323A MX2017010323A (es) | 2015-02-20 | 2016-02-19 | Formulaciones farmaceuticas de inhibidor de esterasa c1. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180036394A1 (enExample) |
| EP (1) | EP3258911A1 (enExample) |
| JP (1) | JP6516855B2 (enExample) |
| KR (1) | KR20170118856A (enExample) |
| CN (1) | CN107257683A (enExample) |
| AU (1) | AU2016221627A1 (enExample) |
| BR (1) | BR112017017685A2 (enExample) |
| CA (1) | CA2977090A1 (enExample) |
| IL (1) | IL253824A0 (enExample) |
| MX (1) | MX2017010323A (enExample) |
| RU (1) | RU2017132449A (enExample) |
| SG (1) | SG11201706019XA (enExample) |
| WO (1) | WO2016131958A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562149A (zh) | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
| CA3061279A1 (en) | 2017-05-16 | 2018-11-22 | Octapharma Ag | C1-esterase inhibitor preparation |
| CN120381522B (zh) * | 2025-04-02 | 2026-01-23 | 南方医科大学南方医院 | 一种治疗肝硬化门脉高压的化合物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2758076T3 (en) * | 2011-09-24 | 2019-04-01 | Csl Behring Gmbh | COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR |
| ME02865B (me) * | 2013-03-15 | 2018-04-20 | Shire Viropharma Inc | C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae) |
-
2016
- 2016-02-19 WO PCT/EP2016/053559 patent/WO2016131958A1/en not_active Ceased
- 2016-02-19 KR KR1020177026457A patent/KR20170118856A/ko not_active Withdrawn
- 2016-02-19 RU RU2017132449A patent/RU2017132449A/ru not_active Application Discontinuation
- 2016-02-19 CN CN201680010988.7A patent/CN107257683A/zh active Pending
- 2016-02-19 CA CA2977090A patent/CA2977090A1/en not_active Abandoned
- 2016-02-19 BR BR112017017685A patent/BR112017017685A2/pt not_active Application Discontinuation
- 2016-02-19 AU AU2016221627A patent/AU2016221627A1/en not_active Abandoned
- 2016-02-19 EP EP16705521.9A patent/EP3258911A1/en not_active Withdrawn
- 2016-02-19 US US15/551,256 patent/US20180036394A1/en not_active Abandoned
- 2016-02-19 MX MX2017010323A patent/MX2017010323A/es unknown
- 2016-02-19 JP JP2017543934A patent/JP6516855B2/ja not_active Expired - Fee Related
- 2016-02-19 SG SG11201706019XA patent/SG11201706019XA/en unknown
-
2017
- 2017-08-03 IL IL253824A patent/IL253824A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL253824A0 (en) | 2017-09-28 |
| KR20170118856A (ko) | 2017-10-25 |
| BR112017017685A2 (pt) | 2018-04-10 |
| CA2977090A1 (en) | 2016-08-25 |
| SG11201706019XA (en) | 2017-09-28 |
| WO2016131958A1 (en) | 2016-08-25 |
| AU2016221627A1 (en) | 2017-08-17 |
| CN107257683A (zh) | 2017-10-17 |
| RU2017132449A3 (enExample) | 2019-09-05 |
| JP6516855B2 (ja) | 2019-05-22 |
| JP2018509398A (ja) | 2018-04-05 |
| RU2017132449A (ru) | 2019-03-21 |
| US20180036394A1 (en) | 2018-02-08 |
| EP3258911A1 (en) | 2017-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MY200356A (en) | Kras g12c inhibitors | |
| PH12020550792A1 (en) | Compounds useful for inhibiting cdk7 | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| MY199220A (en) | Heterocyclic compounds as immunomodulators | |
| PH12017500802B1 (en) | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | |
| SA516380290B1 (ar) | نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة | |
| MD4650B1 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
| PH12014502699A1 (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| MY179781A (en) | Biaryl inhibitors of bruton's tyrosine kinase | |
| MX2021006035A (es) | Formulaciones cannabinoides estables. | |
| EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
| GEAP201814248A (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12017502051A1 (en) | TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
| GEAP201814485A (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
| PH12014502056A1 (en) | 3,5-diaminopyrazole kinase inhibitors | |
| WO2015015378A3 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| NZ708821A (en) | Lfa-1 inhibitor formulations | |
| PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| PH12018501285A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| TN2018000057A1 (en) | Compounds useful for inhibiting ror-gamma-t. | |
| EP4410376A3 (en) | Cd200 inhibitors and methods of use thereof | |
| BR112017017685A2 (pt) | formulações farmacêuticas de inibidor de c1 esterase | |
| PH12017501334A1 (en) | 3,5-diaminopyrazole kinase inhibitors |